Depletion of essential mycobacterial gene glmM reduces pathogen survival and induces host-protective immune responses against tuberculosis.
Meetu AgarwalAshima BhaskarBiplab SinghaSuparba MukhopadhyayIsha PahujaArchna SinghShivam ChaturvediNisheeth AgarwalVed Prakash DwivediVinay Kumar NandicooriPublished in: Communications biology (2024)
The limitations of TB treatment are the long duration and immune-dampening effects of anti-tuberculosis therapy. The Cell wall plays a crucial role in survival and virulence; hence, enzymes involved in its biosynthesis are good therapeutic targets. Here, we identify Mycobacterium tuberculosis (Mtb) GlmM, (GlmM Mtb ) engaged in the UDP-GlcNAc synthesis pathway as an essential enzyme. We generated a conditional knockdown strain, Rv-glmM kD using the CRISPR interference-mediated gene silencing approach. Depletion of GlmM Mtb affects the morphology and thickness of the cell wall. The Rv-glmM kD strain attenuated Mtb survival in vitro, in the host macrophages (ex vivo), and in a murine mice infection model (in vivo). Results suggest that the depletion of GlmM Mtb induces M1 macrophage polarization, prompting a pro-inflammatory cytokine response, apparent from the upregulation of activation markers, including IFNɣ and IL-17 that resists the growth of Mtb. These observations provide a rationale for exploring GlmM Mtb as a potential therapeutic target.
Keyphrases
- mycobacterium tuberculosis
- cell wall
- pulmonary tuberculosis
- immune response
- escherichia coli
- staphylococcus aureus
- clinical trial
- crispr cas
- cell proliferation
- optical coherence tomography
- poor prognosis
- free survival
- stem cells
- computed tomography
- metabolic syndrome
- magnetic resonance
- cystic fibrosis
- inflammatory response
- candida albicans
- smoking cessation
- biofilm formation
- hiv infected
- risk assessment
- combination therapy
- transcription factor
- replacement therapy
- diffusion weighted imaging
- cell therapy